Renal Biopsy in Type 2 Diabetic Patients

Eugenia Espinel, Irene Agraz, Meritxell Ibernon, Natalia Ramos, Joan Fort, Daniel Serón, Eugenia Espinel, Irene Agraz, Meritxell Ibernon, Natalia Ramos, Joan Fort, Daniel Serón

Abstract

The majority of diabetic patients with renal involvement are not biopsied. Studies evaluating histological findings in renal biopsies performed in diabetic patients have shown that approximately one third of the cases will show pure diabetic nephropathy, one third a non-diabetic condition and another third will show diabetic nephropathy with a superimposed disease. Early diagnosis of treatable non-diabetic diseases in diabetic patients is important to ameliorate renal prognosis. The publication of the International Consensus Document for the classification of type 1 and type 2 diabetes has provided common criteria for the classification of diabetic nephropathy and its utility to stratify risk for renal failure has already been demonstrated in different retrospective studies. The availability of new drugs with the potential to modify the natural history of diabetic nephropathy has raised the question whether renal biopsies may allow a better design of clinical trials aimed to delay the progression of chronic kidney disease in diabetic patients.

Keywords: diabetic nephropathy; histology; kidney biopsy; type 2 diabetes.

Figures

Figure 1
Figure 1
Natural history of diabetic nephropathy. There is a poor correlation between renal function deterioration, degree of albuminuria and histological findings. UAER: Urinary albumin excretion rate; CKD: chronic kidney disease; ESRS: end stage renal disease; * mg/gr creatinine; ** mL/mint/1.73 m2.
Figure 2
Figure 2
A patient with nephrotic syndrome, type 2 diabetes and hepatitis C virus associated crioglobulinemia. (a) Hematoxilyn-eosin at 100× magnification showing a glomerulus with mesangial expansion and another with glomerular thombi; (b) periodic acid Schiff (PAS) stain at 400× magnification of the glomerulus showing thrombi; (c) same glomerular section at 400× magnification stained with Masson’s trichrome (d) immunohistochemistry showing subendothelial C3 deposition in the glomerular lumen.

References

    1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047.
    1. Martínez-Castelao A., de Alvaro F., Górriz J.L. Epidemiology of diabetic nephropathy in Spain. Kidney Int. Suppl. 2005;68:S20–S24. doi: 10.1111/j.1523-1755.2005.09905.x.
    1. Torres I.V., Donlo I.C. Control of type 2 diabetes mellitus in Spain today: Identification of the main obstacles in daily clinical practice. Med. Clin. 2013;141(Suppl. S2):3–6.
    1. Gu K., Cowie C.C., Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21:1138–1145.
    1. Bailey R.A., Wang Y., Zhu V., Rupnow M.F.T. Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res. Notes. 2014;7 doi: 10.1186/1756-0500-7-415.
    1. Collins A.J., Foley R.N., Herzog C., Chavers B.M., Gilbertson D., Ishani A., Kasiske B.L., Liu J., Mau L.W., McBean M., et al. Excerpts from the US renal data system 2009 annual data report. Am. J. Kidney Dis. 2010;55(Suppl. S1):1–420.
    1. Diabetic Nephropathy Diabetes Care. [(accessed on 10 March 2015)]; Available online: .
    1. Nelson R.G., Tuttle K.R. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif. 2007;25:112–114. doi: 10.1159/000096407.
    1. Tervaert T.W.C., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B., Ferrario F., Fogo A.B., Haas M., de Heer E., et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. JASN. 2010;21:556–563. doi: 10.1681/ASN.2010010010.
    1. Sharma S.G., Bomback A.S., Radhakrishnan J., Herlitz L.C., Stokes M.B., Markowitz G.S., D’Agati V.D. The modern spectrum of renal biopsy findings in patients with diabetes. Clin. J. Am. Soc. Nephrol. 2013;8:1718–1724. doi: 10.2215/CJN.02510213.
    1. Gonzalez Suarez M.L., Thomas D.B., Barisoni L., Fornoni A. Diabetic nephropathy: Is it time yet for routine kidney biopsy? World J. Diabetes. 2013;4:245–255.
    1. Parving H.H., Hommel E., Mathiesen E., Skøtt P., Edsberg B., Bahnsen M., Lauritzen M., Hougaard P., Lauritzen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br. Med. J. Clin. Res. 1988;296:156–160. doi: 10.1136/bmj.296.6616.156.
    1. Christensen P.K., Larsen S., Horn T., Olsen S., Parving H.H. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int. 2000;58:1719–1731. doi: 10.1046/j.1523-1755.2000.00333.x.
    1. Wong T.Y.H., Choi P.C.L., Szeto C.C., To K.F., Tang N.L.S., Chan A.W., Li P.K., Lai F.M. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care. 2002;25:900–905. doi: 10.2337/diacare.25.5.900.
    1. Kramer H.J., Nguyen Q.D., Curhan G., Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–3277. doi: 10.1001/jama.289.24.3273.
    1. Shimizu M., Furuichi K., Yokoyama H., Toyama T., Iwata Y., Sakai N., Kaneko S., Wada T. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin. Exp. Nephrol. 2014;18:305–312. doi: 10.1007/s10157-013-0870-0.
    1. Fioretto P., Mauer M., Brocco E., Velusi M., Frigato F., Muollo B., Sambataro M., Abaterusso C., Baggio B., Crepaldi G., et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1569–1576. doi: 10.1007/s001250050616.
    1. Ritz E. Clinical manifestations and natural history of diabetic kidney disease. Med. Clin. N. Am. 2013;97:19–29. doi: 10.1016/j.mcna.2012.10.008.
    1. Solez K., Axelsen R.A., Benediktsson H., Burdick J.F., Cohen A.H., Colvin R.B., Croker B.P., Droz D., Dunnill M.S., Halloran P.F., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int. 1993;44:411–422. doi: 10.1038/ki.1993.259.
    1. Cattran D.C., Coppo R., Cook H.T., Feehally J., Roberts I.S., Troyanov S., Alpers C.E., Amore A., Barratt J., Berthoux F., et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–545. doi: 10.1038/ki.2009.243.
    1. Weening J.J., D’Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 2004;15:241–250. doi: 10.1097/01.ASN.0000108969.21691.5D.
    1. D’Agati V.D., Fogo A.B., Bruijn J.A., Jennette J.C. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am. J. Kidney Dis. 2004;43:368–382. doi: 10.1053/j.ajkd.2003.10.024.
    1. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., Campbell P.M., Cascalho M., Collins A.B., Demetris A.J., et al. Banff ′05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’) Am. J. Transplant. 2007;7:518–526. doi: 10.1111/j.1600-6143.2006.01688.x.
    1. Haas M., Sis B., Racusen L.C., Solez K., Glotz D., Colvin R.B., Castro M.C., David D.S., David-Neto E., Bagnasco S.M., et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014;14:272–283. doi: 10.1111/ajt.12590.
    1. Fioretto P., Mauer M. Diabetic nephropathy: Diabetic nephropathy-challenges in pathologic classification. Nat. Rev. Nephrol. 2010;6:508–510. doi: 10.1038/nrneph.2010.96.
    1. Oh S.W., Kim S., Na K.Y., Chae D.-W., Kim S., Jin D.C., Chin H.J. Clinical implications of pathologic diagnosis and classification for diabetic nephropathy. Diabetes Res. Clin. Pract. 2012;97:418–424. doi: 10.1016/j.diabres.2012.03.016.
    1. Mise K., Hoshino J., Ubara Y., Sumida K., Hiramatsu R., Hasegawa E., Yamanouchi M., Hayami N., Suwabe T., Sawa N., et al. Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrol. Dial. Transplant. 2014;29:109–118. doi: 10.1093/ndt/gft349.
    1. Okada T., Nagao T., Matsumoto H., Nagaoka Y., Wada T., Nakao T. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrol. Carlton. 2012;17:68–75. doi: 10.1111/j.1440-1797.2011.01525.x.
    1. An Y., Xu F., Le W., Ge Y., Zhou M., Chen H., Zeng C., Zhang H., Liu Z. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol. Dial. Transplant. 2015;30:257–266. doi: 10.1093/ndt/gfu250.
    1. Mise K., Hoshino J., Ueno T., Hazue R., Sumida K., Hiramatsu R., Hasegawa E., Yamanouchi M., Hayami N., Suwabe T., et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab. Res. Rev. 2014 doi: 10.1002/dmrr.2633.
    1. Miller K., Michael A.F. Immunopathology of renal extracellular membranes in diabetes mellitus. Specificity of tubular basement-membrane immunofluorescence. Diabetes. 1976;25:701–708. doi: 10.2337/diab.25.8.701.
    1. De Zeeuw D., Akizawa T., Audhya P., Bakris G.L., Chin M., Christ-Schmidt H., Goldsberry A., Houser M., Krauth M., Lambers Heerspink H.J., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 2013;369:2492–2503. doi: 10.1056/NEJMoa1306033.
    1. Lewis E.J., Greene T., Spitalewiz S., Blumenthal S., Berl T., Hunsicker L.G., Pohl M.A., Rohde R.D., Raz I., Yerushalmy Y., et al. Pyridorin in type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 2012;23:131–136. doi: 10.1681/ASN.2011030272.
    1. Navarro-González J.F., Mora-Fernández C., Muros de Fuentes M., Chahin J., Méndez M.L., Gallego E., Macía M., del Castillo N., Rivero A., Getino M.A., et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial. J. Am. Soc. Nephrol. 2015;26:220–229. doi: 10.1681/ASN.2014010012.
    1. Chan G.C., Tang S.C. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol. Dial. Transplant. 2015 doi: 10.1093/ndt/gfu411.
    1. Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T., Drummond K., Donnelly S., Goodyer P., Gubler M.C., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009;361:40–51. doi: 10.1056/NEJMoa0808400.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit